Collectively, our data demonstrated that there was a greater response of the NPC cell lines to co-inhibition of MCL-1 and BCL-XL compared to co-inhibition of MCL-1 and BCL-2, suggesting that co-inhibition of MCL-1 and BCL-XL are better therapeutic targets for killing NPC cells. This evidence concerns the gene MCL1 and nasopharyngeal carcinoma.